Kavalactone product

Abstract

The present invention is a method for enhancing the efficacy of an active ingredient in a human comprising: administering to said human a product comprising: a kavalactone component and an active ingredient, wherein said active ingredient is selected from the group consisting of a therapeutic, a pharmaceutical, a nutraceutical and a botanical, and wherein said kavalactone component comprises a methysticin component, a dihydromethysticin component, a desmethoxyyangonin component, a yangonin component, a dihydrokavain component, and a kavain component, and wherein said kavalactone component is between about 0.1% to about 75%, by mass, of said product.

1 - 16 . (canceled)  
     
     
         17 . A method for enhancing the efficacy of an active ingredient in a human, comprising: 
 administering to the human in need thereof a product comprising:    a kavalactone component and an active ingredient;    wherein the kavalactone component comprises a methysticin component, a dihydromethysticin component, a yangonin component, a desmethoxyyangonin component, a kavain component, and a dihydrokavain component;    wherein the kavalactone component is between about 0.1% and about 75%, by mass, of said product; and    wherein the active ingredient is selected from the group consisting of  Areca catechu, Piper betel, Ptychopetalum olacoides, Ilex paraguariensis, Echinacea purpurea, Echinacea angustifolia, Echinacea pallida, Panax quinquefolius, Panax ginseng, Curcuma longa, Lactuca virosa, Lactuca indica, Zingiber officinalis, Salix purpurea, Salix daphnoides, Prunus avium, Prunus cerasus, Pfaffia paniculata, Tumera diffusa, Epimedium  species,  Terrestris tribulus, Rhodiola rosea, Astragalus membranaceus, Eucommia ulmoides, Gastrodia elata, Passiflora incarnata, Uncaria rhyncophylla,  and  coleus forskohlii.      
     
     
         18 . The method of  claim 17 , wherein the kavalactone component is present in an amount from about 5% to about 35%, by mass, of the product.  
     
     
         19 . The method of  claim 17 , wherein the product is a dry flowable powder.  
     
     
         20 . The method of  claim 17 , wherein the product is a paste or liquid extract.  
     
     
         21 . The method of  claim 17 , wherein the product is a rapid dissolve tablet.  
     
     
         22 . The method of  claim 17 , wherein the dihydromethysticin component is less than about five percent by weight of the kavalactone component.  
     
     
         23 . The method of  claim 17 , wherein the desmethoxyyangonin component is less than about four percent by weight of the kavalactone component.  
     
     
         24 . The method of  claim 17 , wherein the yangonin component is less than about one percent by weight of the kavalactone component.  
     
     
         25 . The method of  claim 17 , wherein the dihydrokavain component is greater than about fifty percent by weight of the kavalactone component.  
     
     
         26 . The method of  claim 17 , wherein the kavain component is greater than about thirty-eight percent by weight of the kavalactone component.  
     
     
         27 . A method for enhancing the efficacy of an active ingredient in a human, comprising: 
 administering to the human in need thereof a product comprising:    a kavalactone component and an active ingredient;    wherein the kavalactone component comprises a methysticin component, a dihydromethysticin component, a yangonin component, a desmethoxyyangonin component, a kavain component, and a dihydrokavain component;    wherein the kavalactone component is between about 0.1% and about 75%, by mass, of said product; and    wherein the active ingredient is selected from the group consisting of  Scutelleria baicalensis, Scutelleria laterifolia, Valeriana officinalis, Rosemary officinalis, Matricaria chamomilla, Eschscholzia californica,  and  Avena sativa.      
     
     
         28 . The method of  claim 27 , wherein the kavalactone component is present in an amount from about 5% to about 35%, by mass, of the product.  
     
     
         29 . The method of  claim 27 , wherein the product is a dry flowable powder.  
     
     
         30 . The method of  claim 27 , wherein the product is a paste or liquid extract.  
     
     
         31 . The method of  claim 27 , wherein the product is a rapid dissolve tablet.  
     
     
         32 . The method of  claim 27 , wherein the dihydromethysticin component is less than about five percent by weight of the kavalactone component.  
     
     
         33 . The method of  claim 27 , wherein the desmethoxyyangonin component is less than about four percent by weight of the kavalactone component.  
     
     
         34 . The method of  claim 27 , wherein the yangonin component is less than about one percent by weight of the kavalactone component.  
     
     
         35 . The method of  claim 27 , wherein the dihydrokavain component is greater than about fifty percent by weight of the kavalactone component.  
     
     
         36 . The method of  claim 27 , wherein the kavain component is greater than about thirty-eight percent by weight of the kavalactone component.